Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
45
PALI Quote, Financials, Valuation and Earnings
Last price:
$1.82
Seasonality move
:
-0.03%
Day range:
$1.78 - $1.85
52-week range:
$0.53 - $2.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
84.13x
Volume:
3.4M
Avg. volume:
5.8M
1-year change:
21.48%
Market cap:
$270.1M
Revenue:
--
EPS (TTM):
-$4.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
-- | -$0.03 | -100% | -91.4% | $13.40 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$834.6M | $0.71 | 11.96% | 37.26% | $90.74 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
$1.81 | $13.40 | $270.1M | -- | $0.00 | 0% | -- |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$56.85 | $90.74 | $10.9B | 21.30x | $0.00 | 0% | 3.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.15 | $0.85 | $397.4M | 5.29x | $0.80 | 0% | 6.12x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
6.16% | 2.887 | 2.63% | 1.50x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.914 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
-$1K | -$2.9M | -212.65% | -222.18% | -- | -$3.6M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Palisade Bio, Inc. vs. Competitors
-
Which has Higher Returns PALI or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of -3.91%. Palisade Bio, Inc.'s return on equity of -222.18% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About PALI or BMRN?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 640.33%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $90.74 which suggests that it could grow by 59.61%. Given that Palisade Bio, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Palisade Bio, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is PALI or BMRN More Risky?
Palisade Bio, Inc. has a beta of 1.432, which suggesting that the stock is 43.173% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.267, suggesting its less volatile than the S&P 500 by 73.343%.
-
Which is a Better Dividend Stock PALI or BMRN?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or BMRN?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Palisade Bio, Inc.'s net income of -$2.9M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 3.60x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M
-
Which has Higher Returns PALI or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of 10.24%. Palisade Bio, Inc.'s return on equity of -222.18% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About PALI or FOLD?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 640.33%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Palisade Bio, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Palisade Bio, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is PALI or FOLD More Risky?
Palisade Bio, Inc. has a beta of 1.432, which suggesting that the stock is 43.173% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock PALI or FOLD?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or FOLD?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Palisade Bio, Inc.'s net income of -$2.9M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns PALI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of -255.85%. Palisade Bio, Inc.'s return on equity of -222.18% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PALI or NBY?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 640.33%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.02%. Given that Palisade Bio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Palisade Bio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PALI or NBY More Risky?
Palisade Bio, Inc. has a beta of 1.432, which suggesting that the stock is 43.173% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock PALI or NBY?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or NBY?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Palisade Bio, Inc.'s net income of -$2.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 6.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M NBYNovaBay Pharmaceuticals, Inc.6.12x 5.29x $521K -$1.3M
-
Which has Higher Returns PALI or PTN?
Palatin Technologies has a net margin of -- compared to Palisade Bio, Inc.'s net margin of --. Palisade Bio, Inc.'s return on equity of -222.18% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PALI or PTN?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 640.33%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Palisade Bio, Inc., analysts believe Palatin Technologies is more attractive than Palisade Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 PTNPalatin Technologies0 0 0 -
Is PALI or PTN More Risky?
Palisade Bio, Inc. has a beta of 1.432, which suggesting that the stock is 43.173% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PALI or PTN?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or PTN?
Palisade Bio, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Palisade Bio, Inc.'s net income of -$2.9M is higher than Palatin Technologies's net income of --. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PALI or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of --. Palisade Bio, Inc.'s return on equity of -222.18% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PALI or TOVX?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 640.33%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3386.06%. Given that Theriva Biologics, Inc. has higher upside potential than Palisade Bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Palisade Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is PALI or TOVX More Risky?
Palisade Bio, Inc. has a beta of 1.432, which suggesting that the stock is 43.173% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock PALI or TOVX?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or TOVX?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Palisade Bio, Inc.'s net income of -$2.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Alerts
Sell
11
CVLT alert for Jan 28
Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.
Buy
69
SANM alert for Jan 28
Sanmina Corp. [SANM] is down 21.58% over the past day.
Sell
35
HUM alert for Jan 28
Humana, Inc. [HUM] is down 21.11% over the past day.
